HIMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Hims & Hers Health Inc. is not a good buy for a beginner investor with a long-term strategy at this time. The stock faces significant regulatory risks, declining financial performance, and mixed analyst sentiment. While hedge funds are buying, the overall outlook is uncertain, and the lack of strong proprietary trading signals further supports a cautious stance.
The technical indicators show a bearish trend with SMA_200 > SMA_20 > SMA_5. The MACD is positive but expanding, and RSI is neutral at 44.123. Key support is at 14.245, and resistance is at 16.667. The stock is trading pre-market at 15.99, slightly above the pivot of 15.456, but the overall trend remains weak.
Hedge funds have significantly increased their buying activity by 211.82% over the last quarter. The company's revenue increased 28.41% YoY in Q4 2025, indicating some growth momentum.
The FDA issued warning letters to Hims & Hers and other telehealth companies, leading to a decline in stock price. Analysts have lowered price targets significantly, citing regulatory risks, slowing revenue growth, and weak Q1 guidance. JPMorgan Chase reduced its stake in the company from 8.1% to 1.7%.
In Q4 2025, revenue increased by 28.41% YoY to $617.8M, but net income dropped by 20.84% YoY to $20.6M. EPS declined by 27.27% YoY to 0.08, and gross margin fell to 71.94%, down 6.34% YoY. These trends indicate declining profitability despite revenue growth.
Analysts have downgraded the stock and significantly reduced price targets. Ratings include Underperform, Hold, and Neutral, with price targets ranging from $12.50 to $25. Concerns include regulatory risks, weak Q1 guidance, and slowing revenue growth.
